Updates from day 3 of the Huntington’s Disease Therapeutics Conference: huntingtin protein - and lowering it
A surprising new paper sheds light on the role of the HD gene early in development. Should we worry?
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta - day 2
Work with genome editing techniques (zinc fingers and CRISPR) brings these tools closer to use in HD clinical trials
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore